Metastatic Castration-Resistant Prostate Cancer
Enzalutamide confers small benefit vs. abiraterone in metastatic prostate cancer
Enzalutamide conferred small but statistically significant improvements in outcomes vs. abiraterone acetate for men with metastatic castration-resistant prostate cancer, according to retrospective study results.
Combination extends survival in metastatic prostate cancer
The addition of talazoparib to enzalutamide extended OS among men with metastatic castration-resistant prostate cancer, according to the agent’s manufacturer.
Circulating tumor cell count predicts prostate cancer survival, can help tailor treatment
A blood test for men at the time of a metastatic prostate cancer diagnosis may predict treatment response and survival, according to study results.
Prostate Cancer updates: Test identifies aggressive disease, diet affects progression risk
National Prostate Cancer Awareness Month is observed every September.
VIDEO: CHAARTED 2 examines combination therapy for patients previously on docetaxel
In this video, Alexander Chehrazi-Raffle, MD, discusses the results of the CHAARTED 2 cooperative group studies into metastatic castration-resistant prostate cancer, presented at ASCO Annual Meeting.
VIDEO: Use of precision medicine ‘encouraging’ in prostate cancer treatment
In this video, Alexander Chehrazi-Raffle, MD, discusses the results of a study into the use of new precision medicine therapies in prostate cancer, presented at ASCO Annual Meeting.
VIDEO: Therapy binds human kallikrein 2 in prostate cancer
In this video, Alexander Chehrazi-Raffle, MD, discusses the results of a study into the use of JNJ-6520 in prostate cancer, presented at ASCO Annual Meeting.
VIDEO: Castration-resistant prostate cancer quality of life studies favor lutetium arms
In this video, Alexander Chehrazi-Raffle, MD, discusses the results of three studies into quality-of-life outcomes in metastatic castration-resistant prostate cancer, presented at ASCO Annual Meeting.
VIDEO: CYCLONE 2 probes abemaciclib and abiraterone in prostate cancer
In this video, Alexander Chehrazi-Raffle, MD, discusses the results of the CYCLONE 2 study into metastatic castration-resistant prostate cancer, presented at ASCO Annual Meeting.
VIDEO: Proteolysis-targeting chimeras show promising results in prostate cancer
In this video, Alexander Chehrazi-Raffle, MD, discusses the results of a phase 1/phase 2 study into proteolysis-targeting chimeras in prostate cancer treatment, presented at ASCO Annual Meeting.